Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PLG | P00747 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | PLAT | P00750 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 6/20 | 0.39 |
| ▸ | CTSK | P43235 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRB2 | P62993 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205687 | 1.00 | CYP2C19 (0.47) | CYP2C19SMN1; SMN2HDAC8F2PLG | |
| SCHEMBL10293316 | 0.90 | F2 (0.41) | CYP2C19SMN1; SMN2HDAC8F2PLG | |
| SCHEMBL8909381 | 0.90 | F2 (0.41) | CYP2C19SMN1; SMN2HDAC8F2PLG | |
| SCHEMBL846781 | 0.87 | CYP2C19 (0.49) | CYP2C19SMN1; SMN2F2PLGPLAU | |
| SCHEMBL10122830 | 0.85 | CYP2C19 (0.47) | CYP2C19SMN1; SMN2HDAC8F2PLG | |
| SCHEMBL888740 | 0.85 | CYP2C19 (0.47) | CYP2C19SMN1; SMN2HDAC8F2PLG | |
| SCHEMBL8906641 | 0.80 | CTSS (0.52) | CYP2C19CTSSCTSKMEN1ALDH1A1 | |
| SCHEMBL8906760 | 0.80 | CTSS (0.52) | CYP2C19CTSSCTSKMEN1ALDH1A1 | |
| SCHEMBL8909419 | 0.78 | NPC1 (0.57) | SMN1; SMN2HDAC8ITGB3ITGA2B | |
| SCHEMBL8907714 | 0.78 | ACACB (0.43) | ACACBCTSSCTSKALDH1A1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822444-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8796466-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120277266-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-01 | — | — | US | disclosed |
| US-8211928-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-03 | — | — | US | disclosed |
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-02 | — | — | US | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4311/4885SMN1; SMN2 4414/4885HDAC8 1581/4885 |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4311/4885SMN1; SMN2 4414/4885HDAC8 1581/4885 |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4311/4885SMN1; SMN2 4414/4885HDAC8 1581/4885 |
| US-20120277266-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4311/4885SMN1; SMN2 4414/4885HDAC8 1581/4885 |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4378/4885SMN1; SMN2 4418/4885HDAC8 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.